Ranbaxy Laboratories is looking forward to achieve some big achievements in the coming two years. Its parent company, Daiichi is confident that Ranbaxy Labs will end all the issues regarding manufacturing facilities and other regulatory issues with US FDA, very soon.

In September, 2008 the American drug regulator had banned the sale of some of the drugs manufactured by Ranbaxy. Around 30 drugs were banned in the US. The regulator has accused Ranbaxy of using defective manufacturing process for several life-saving drugs.

However, the President of Daiichi, Takashi Shoda in a statement has said that the ban is expected to be lifted by the year 2012. The parent company has also expressed its anticipation in preparing a number of innovative products.

Both Daiichi and Ranbaxy are looking forward for a strong business model in the coming years with some quality inclusion in product lines.

Apart from that, the duo is thinking of working on vaccines, generics and OTC products. Shoda has also revealed that the earning contribution of Ranbaxy in Daiichi is expected to go up by 23 per cent by 2012.